How to buy MiNK Therapeutics stock (INKT)

Clinical stage biotechnology company MiNK Therapeutics wrapped its initial public offering, selling 3.333 million shares at $12 each, the low end of its $12 to $14 range.

Shares of INKT will commence trading on the Nasdaq later today, but the stock is available for limit orders on Robinhood and other platforms.

Our top picks for where to buy Mink Therapeutics stock

Buy MiNK Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

MiNK Therapeutics stock price (NASDAQ: INKT)

Use our graph to track the performance of INKT stocks over time.

MiNK Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$0.58
52-week range	$0.46 - $1.90
50-day moving average more info button	$0.68
200-day moving average more info button	$0.84
Wall St. target price	$6.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.37

Is it a good time to buy MiNK Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MiNK Therapeutics price performance over time

Historical closes compared with the close of $0.5279 from 2024-12-26

1 week (2024-12-20)	0.74%
1 month (2024-11-27)	-26.69%
3 months (2024-09-27)	-29.83%
6 months (2024-06-27)	-43.24%

1 year (2023-12-27)	-48.75%
2 years (2022-12-27)	-77.15%
3 years (2021-12-27)	4.3
5 years (2019-12-24)	N/A

MiNK Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-97.25%
Return on equity TTM	-1238.98%
Profit margin	0%
Book value	$-0.52
Market Capitalization more info button	$21 million

TTM: trailing 12 months

MiNK Therapeutics share dividends

We're not expecting MiNK Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.53% forward annual dividend yield)
• Sanofi ADR (SNY.US) (4.27% forward annual dividend yield)

MiNK Therapeutics share price volatility

Over the last 12 months, MiNK Therapeutics's shares have ranged in value from as little as $0.4632 up to $1.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MiNK Therapeutics's is 0.048. This would suggest that MiNK Therapeutics's shares are less volatile than average (for this exchange).

To put MiNK Therapeutics's beta into context you can compare it against those of similar companies.

• Pfizer (PFE.US): 0.615
• Sanofi ADR (SNY.US): 0.445
• Biogen (BIIB.US): -0.061

MiNK Therapeutics overview

MiNK Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York.

Frequently asked questions

What percentage of MiNK Therapeutics is owned by insiders or institutions?
Currently 74.648% of MiNK Therapeutics shares are held by insiders and 2.253% by institutions. How many people work for MiNK Therapeutics?
Latest data suggests 31 work at MiNK Therapeutics. When does the fiscal year end for MiNK Therapeutics?
MiNK Therapeutics's fiscal year ends in December. Where is MiNK Therapeutics based?
MiNK Therapeutics's address is: 149 Fifth Avenue, New York, NY, United States, 10010 What is MiNK Therapeutics's ISIN number?
MiNK Therapeutics's international securities identification number is: US6036931029